Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) Insider Scott Biller unloaded 4,500 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $42.39, for a total value of $190,755.00. Following the completion of the transaction, the insider now directly owns 30,000 shares in the company, valued at approximately $1,271,700. The sale was disclosed in a legal filing with the SEC, which is available at this link.

AGIO has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. Separately, analysts at JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday, April 7th. They now have a $55.00 price target on the stock, up previously from $40.00. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Agios Pharmaceuticals from $35.00 to $40.00 in a research note on Friday, March 28th. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $49.48.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up 1.22% on Monday, hitting $43.81. The stock had a trading volume of 173,092 shares. Agios Pharmaceuticals has a one year low of $15.77 and a one year high of $49.79. The stock has a 50-day moving average of $41.54 and a 200-day moving average of $30.29. The company’s market cap is $1.384 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.06. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.19 million. Analysts expect that Agios Pharmaceuticals will post $-1.32 EPS for the current fiscal year.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.